Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Acessa™ by Halt Medical receives FDA approval for treating uterine fibroids

LAS VEGAS, Nov. 6, 2012 /PRNewswire/ -- Halt Medical, Inc. announced today at the opening session of the AAGL Global Congress on Minimally Invasive Gynecology that the FDA has cleared Acessa™, a revolutionary new medical technology for treating millions of women suffering from uterine fibroids.  "At last, a fibroid treatment that patients and physicians have been waiting for," said Dr. David Levine, former Board Member of the American Association of Gynecological Laparoscopists (AAGL). 

"Acessa is the first product cleared anywhere in the world that can be used by gynecologists to treat all fibroid symptoms and types," said Jeffrey Cohen, Halt Medical's Chief Executive Officer.

According to the Centers for Disease Control (CDC), fibroids are the leading cause for hysterectomy procedures worldwide.  "It's estimated that 97% of women with fibroids choose to suffer with their symptoms rather than having their uterus removed.  We're about to change all that," said Mr. Cohen. "Finally, gynecologists will have an alternative to hysterectomy for their fibroid patients."

Acessa is used in a minimally invasive same-day surgery procedure where a slender handpiece is used to deliver radiofrequency (RF) energy to the fibroid.  After treatment, the fibroid is re-absorbed by the surrounding tissue.

In traditional fibroid surgery, layers of healthy tissue are cut through to gain access to the tumor or to remove the uterus entirely.  This can lead to complications, significant pain, and long recovery times.  Acessa treats just the fibroids, preserving the normal function of the uterus. Patients typically go home the same day with little pain and are back to regular activities in 5 days or less. According to Mr. Cohen, "The high patient satisfaction and low re-intervention rates seen in our clinical studies provides the opportunity for the healthcare system to replace radical surgery and save billions of dollars."

Acessa is already being used to treat women at medical centers in Canada and Europe.  "With compelling results from three clinical studies, we have been anticipating this clearance from the FDA," said Russ DeLonzor, Halt's President and Chief Operating Officer. "We've been expanding our manufacturing operations near San Francisco and are ready to meet the increased demand for Acessa from doctors in the U.S. and abroad."

Two surgeons, Dr. Bruce Lee and Dr. Gordon Epstein, led the team of engineers at Halt Medical to develop Acessa to be the ideal treatment for uterine fibroids.  "The FDA clearance means we can now put this imperative new medical technology in the hands of gynecologists in the U.S., a major milestone for our company," said Mr. Cohen.

For information about Acessa, please visit www.haltmedical.com.

SOURCE Halt Medical, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining ...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establis...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of application...
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the ...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offe...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE